Profile data is unavailable for this security.
About the company
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
- Revenue in SEK (TTM)104.24m
- Net income in SEK-200.07m
- Incorporated2005
- Employees28.00
- LocationVicore Pharma Holding ABKornhamnstorg 53STOCKHOLM 111 27SwedenSWE
- Phone+46 317880560
- Websitehttps://vicorepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arcticzymes Technologies ASA | 111.72m | 14.08m | 864.49m | 68.00 | 61.32 | 2.82 | 43.28 | 7.74 | 0.2867 | 0.2867 | 2.27 | 6.24 | 0.3485 | 0.5349 | 6.83 | 1,706,250.00 | 4.39 | 15.58 | 4.63 | 17.22 | 94.39 | 96.69 | 12.60 | 33.23 | 17.25 | -- | 0.0298 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
Alligator Bioscience AB | 45.71m | -234.30m | 1.01bn | 51.00 | -- | -- | -- | 22.06 | -0.362 | -0.362 | 0.0696 | -0.0125 | 0.2653 | -- | 9.47 | 788,034.50 | -136.02 | -73.26 | -367.94 | -91.33 | -- | -- | -512.61 | -811.68 | -- | -35.61 | 5.17 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
Egetis Therapeutics AB (publ) | 93.90m | -296.40m | 1.22bn | 32.00 | -- | 3.05 | -- | 13.02 | -1.23 | -1.23 | 0.3884 | 1.37 | 0.1496 | 13.45 | 7.48 | 3,477,778.00 | -33.65 | -33.02 | -40.07 | -36.46 | 92.12 | -- | -224.92 | -357.72 | 1.55 | -24.39 | 0.2158 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
Nightingale Health Oyj | 49.39m | -197.92m | 1.39bn | 84.00 | -- | 2.24 | -- | 28.21 | -0.29 | -0.29 | 0.0723 | 1.37 | 0.0441 | 2.33 | 3.46 | 51,880.95 | -17.67 | -14.59 | -18.99 | -15.99 | 66.45 | 77.81 | -400.73 | -435.73 | 9.74 | -- | 0.0308 | -- | 4.21 | 16.13 | 3.43 | -- | 8.54 | -- |
Diamyd Medical AB | 186.00k | -139.62m | 1.39bn | 25.00 | -- | 7.35 | -- | 7,496.30 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
XSpray Pharma AB (publ) | 0.00 | -214.76m | 1.40bn | 26.00 | -- | 2.58 | -- | -- | -7.05 | -7.05 | 0.00 | 19.79 | 0.00 | -- | -- | 0.00 | -33.11 | -18.38 | -36.76 | -19.26 | -- | -- | -- | -- | 3.50 | -- | 0.0496 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
Nykode Therapeutics ASA | 62.56m | -385.85m | 1.49bn | 179.00 | -- | 0.9605 | -- | 23.76 | -1.29 | -1.29 | 0.2031 | 4.92 | 0.0333 | -- | 1.59 | 375,549.70 | -20.57 | 5.65 | -23.15 | 6.38 | -- | -- | -616.79 | 18.13 | -- | -- | 0.0305 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
Nanoform Finland Oyj | 26.01m | -245.57m | 1.57bn | 174.00 | -- | 1.95 | -- | 60.39 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
Vicore Pharma Holding AB | 104.24m | -200.07m | 1.57bn | 28.00 | -- | 1.86 | -- | 15.09 | -1.76 | -1.76 | 0.9134 | 3.79 | 0.2546 | -- | 64.15 | 4,343,459.00 | -48.87 | -58.65 | -53.82 | -65.58 | -- | -- | -191.92 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
Cereno Scientific AB | 0.00 | -69.48m | 1.85bn | 5.00 | -- | 7.33 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
Devyser Diagnostics AB | 196.00m | -54.20m | 2.21bn | 127.00 | -- | 6.00 | -- | 11.27 | -3.33 | -3.33 | 12.05 | 22.35 | 0.3855 | 1.61 | 5.42 | 1,661,017.00 | -10.68 | -8.97 | -12.15 | -10.15 | 83.11 | 80.14 | -27.70 | -23.91 | 4.01 | -- | 0.1498 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
Data as of Sep 26 2024. Currency figures normalised to Vicore Pharma Holding AB's reporting currency: Swedish Krona SEK
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 31 Dec 2023 | 10.96m | 9.81% |
HBM Partners AG (Investment Management)as of 31 Dec 2023 | 10.87m | 9.73% |
C WorldWide Asset Management Fondsm�glerselskab A/Sas of 31 Dec 2023 | 3.35m | 3.00% |
C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 31 Dec 2023 | 3.35m | 3.00% |
Swedbank Robur Fonder ABas of 31 Dec 2023 | 2.41m | 2.16% |
Handelsbanken Fonder ABas of 31 Jul 2024 | 2.32m | 2.07% |
Medical Strategy GmbHas of 31 May 2023 | 1.13m | 1.01% |
SEB Investment Management ABas of 28 Jun 2024 | 1.03m | 0.92% |
East Capital Financial Services ABas of 31 Jul 2024 | 770.72k | 0.69% |
Andra AP-fondenas of 31 Dec 2023 | 528.75k | 0.47% |
More ▼
Data from 31 Mar 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.